NH SPAC 2
Boditech Med Inc. offers instruments and diagnostic reagents in South Korea and internationally. The company offers instruments, including ichroma II, diagnostic immuno-analyzer to measure the presence of various biomarkers for cardiac, cancer, hormones, infectious diseases, autoimmune diseases, and metabolic diseases; ichroma III, a high-throughput immuno-analyzer that enables simultaneous testi… Read more
NH SPAC 2 (206640) - Net Assets
Latest net assets as of September 2025: ₩237.02 Billion KRW
Based on the latest financial reports, NH SPAC 2 (206640) has net assets worth ₩237.02 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩274.58 Billion) and total liabilities (₩37.56 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩237.02 Billion |
| % of Total Assets | 86.32% |
| Annual Growth Rate | 15.81% |
| 5-Year Change | 86.1% |
| 10-Year Change | N/A |
| Growth Volatility | 19.86 |
NH SPAC 2 - Net Assets Trend (2015–2024)
This chart illustrates how NH SPAC 2's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for NH SPAC 2 (2015–2024)
The table below shows the annual net assets of NH SPAC 2 from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩223.05 Billion | +12.99% |
| 2023-12-31 | ₩197.42 Billion | +20.70% |
| 2022-12-31 | ₩163.56 Billion | +8.25% |
| 2021-12-31 | ₩151.09 Billion | +26.06% |
| 2020-12-31 | ₩119.86 Billion | +62.97% |
| 2019-12-31 | ₩73.55 Billion | +12.57% |
| 2018-12-31 | ₩65.33 Billion | -3.74% |
| 2017-12-31 | ₩67.87 Billion | -9.71% |
| 2016-12-31 | ₩75.17 Billion | +26.32% |
| 2015-12-31 | ₩59.50 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to NH SPAC 2's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 843.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩186.21 Billion | 88.56% |
| Common Stock | ₩23.49 Billion | 11.17% |
| Other Components | ₩575.55 Million | 0.27% |
| Total Equity | ₩210.27 Billion | 100.00% |
NH SPAC 2 Competitors by Market Cap
The table below lists competitors of NH SPAC 2 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
National Aerospace Fasteners Corp
TW:3004
|
$110.90 Million |
|
KB Components AB (publ)
ST:KBC
|
$110.94 Million |
|
ARC Document Solutions Inc
NYSE:ARC
|
$110.98 Million |
|
Wiz Soluções e Corretagem de Seguros S.A
SA:WIZC3
|
$110.99 Million |
|
Speed Tech
TWO:5457
|
$110.79 Million |
|
OLYFF
PINK:OLYFF
|
$110.79 Million |
|
Clinica Baviera
MC:CBAV
|
$110.76 Million |
|
Seoyon E Hwa Co Ltd
KO:200880
|
$110.76 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NH SPAC 2's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 186,198,223,250 to 210,269,476,840, a change of 24,071,253,590 (12.9%).
- Net income of 27,260,388,300 contributed positively to equity growth.
- Dividend payments of 4,395,079,200 reduced retained earnings.
- Share repurchases of 2,829,040,940 reduced equity.
- New share issuances of 135,297,600 increased equity.
- Other factors increased equity by 3,899,687,830.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩27.26 Billion | +12.96% |
| Dividends Paid | ₩4.40 Billion | -2.09% |
| Share Repurchases | ₩2.83 Billion | -1.35% |
| Share Issuances | ₩135.30 Million | +0.06% |
| Other Changes | ₩3.90 Billion | +1.85% |
| Total Change | ₩- | 12.93% |
Book Value vs Market Value Analysis
This analysis compares NH SPAC 2's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.30x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.80x to 1.30x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩3263.52 | ₩12400.00 | x |
| 2017-12-31 | ₩2948.15 | ₩12400.00 | x |
| 2018-12-31 | ₩2823.48 | ₩12400.00 | x |
| 2019-12-31 | ₩3209.87 | ₩12400.00 | x |
| 2020-12-31 | ₩5201.62 | ₩12400.00 | x |
| 2021-12-31 | ₩6688.05 | ₩12400.00 | x |
| 2022-12-31 | ₩7445.22 | ₩12400.00 | x |
| 2023-12-31 | ₩8475.58 | ₩12400.00 | x |
| 2024-12-31 | ₩9567.97 | ₩12400.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NH SPAC 2 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.96%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 19.73%
- • Asset Turnover: 0.54x
- • Equity Multiplier: 1.21x
- Recent ROE (12.96%) is below the historical average (13.25%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -3.32% | -4.95% | 0.56x | 1.21x | ₩-7.91 Billion |
| 2016 | 16.79% | 22.96% | 0.61x | 1.21x | ₩5.10 Billion |
| 2017 | -3.16% | -4.08% | 0.49x | 1.59x | ₩-8.93 Billion |
| 2018 | -2.59% | -2.55% | 0.64x | 1.58x | ₩-8.22 Billion |
| 2019 | 15.84% | 16.00% | 0.72x | 1.38x | ₩4.30 Billion |
| 2020 | 37.95% | 31.56% | 0.88x | 1.36x | ₩33.50 Billion |
| 2021 | 29.36% | 28.13% | 0.82x | 1.27x | ₩29.26 Billion |
| 2022 | 14.77% | 20.45% | 0.60x | 1.20x | ₩7.80 Billion |
| 2023 | 13.93% | 19.33% | 0.59x | 1.22x | ₩7.33 Billion |
| 2024 | 12.96% | 19.73% | 0.54x | 1.21x | ₩6.23 Billion |
Industry Comparison
This section compares NH SPAC 2's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $98,321,642,752
- Average return on equity (ROE) among peers: 7.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NH SPAC 2 (206640) | ₩237.02 Billion | -3.32% | 0.16x | $110.88 Million |
| Shinhung (004080) | $87.31 Billion | 3.50% | 0.52x | $10.80 Million |
| Osang Healthcare Co.,Ltd (036220) | $199.86 Billion | 20.34% | 0.25x | $37.44 Million |
| HansBiomed Corporation (042520) | $43.16 Billion | 11.38% | 0.21x | $246.58 Million |
| JVM Co. Ltd (054950) | $98.83 Billion | 10.23% | 0.72x | $117.37 Million |
| Huvitz Co. Ltd (065510) | $51.68 Billion | 16.97% | 0.32x | $43.64 Million |
| Vieworks Co. Ltd (100120) | $188.04 Billion | 17.80% | 0.28x | $101.54 Million |
| Corentec Co Ltd (104540) | $48.30 Billion | -3.04% | 0.46x | $40.80 Million |
| Hironic Co. Ltd (149980) | $40.72 Billion | 7.13% | 0.15x | $23.71 Million |
| Laseroptek Co., Ltd. (199550) | $-3.94 Billion | 0.00% | 0.00x | $21.68 Million |
| Humasis Co. Ltd (205470) | $229.26 Billion | -13.28% | 0.45x | $48.97 Million |